DDInter987 DDInter1676
Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.[A15638,L33160] Isoprenaline research in the 1940s found that this isopropyl analog of epinephrine dilated the bronchi, as well as raising the heart rate and cardiac output, without vasoconstriction.[A233724,A233729] The US patent from 1943 states that this compound had a wider therapeutic index and a stronger action than [adrenaline]. Isoprenaline was granted FDA approval on 19 February 1948.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Isoprenaline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Phenylephrine
Isoprenaline {u} (Compound) resembles {v} (Compound) Hexoprenaline
Isoprenaline {u} (Compound) resembles {v} (Compound) Isoetharine
Isoprenaline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Levonordefrin
Isoprenaline {u} (Compound) treats {v} (Disease) asthma
Isoprenaline {u} (Compound) binds {v} (Gene) PIK3R2
Isoprenaline {u} (Compound) upregulates {v} (Gene) DHX29
Isoprenaline {u} (Compound) downregulates {v} (Gene) COG2
Isoprenaline {u} (Compound) causes {v} (Side Effect) Flushing
Isoprenaline {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ciclesonide
Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Phenylephrine
Isoprenaline (Compound) resembles Hexoprenaline (Compound)
Isoprenaline (Compound) resembles Isoetharine (Compound)
Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Levonordefrin
Isoprenaline (Compound) treats asthma (Disease)
Isoprenaline (Compound) binds PIK3R2 (Gene)
Isoprenaline (Compound) upregulates DHX29 (Gene)
Isoprenaline (Compound) downregulates COG2 (Gene)
Isoprenaline (Compound) causes Flushing (Side Effect)
Isoprenaline may cause a minor interaction that can limit clinical effects when taken with Ciclesonide